Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Receivables - Other: 2019-2025

Historic Receivables - Other for Voyager Therapeutics (VYGR) over the last 7 years, with Sep 2025 value amounting to $851,000.

  • Voyager Therapeutics' Receivables - Other fell 77.09% to $851,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $851,000, marking a year-over-year decrease of 77.09%. This contributed to the annual value of $676,000 for FY2024, which is 79.77% down from last year.
  • As of Q3 2025, Voyager Therapeutics' Receivables - Other stood at $851,000, which was down 0.00% from $851,000 recorded in Q2 2025.
  • Voyager Therapeutics' Receivables - Other's 5-year high stood at $3.7 million during Q3 2024, with a 5-year trough of $151,000 in Q2 2022.
  • For the 3-year period, Voyager Therapeutics' Receivables - Other averaged around $1.9 million, with its median value being $1.5 million (2024).
  • As far as peak fluctuations go, Voyager Therapeutics' Receivables - Other plummeted by 98.77% in 2021, and later spiked by 2,118.54% in 2023.
  • Voyager Therapeutics' Receivables - Other (Quarterly) stood at $732,000 in 2021, then plummeted by 64.89% to $257,000 in 2022, then skyrocketed by 1,200.00% to $3.3 million in 2023, then plummeted by 79.77% to $676,000 in 2024, then crashed by 77.09% to $851,000 in 2025.
  • Its last three reported values are $851,000 in Q3 2025, $851,000 for Q2 2025, and $487,000 during Q1 2025.